JP2013505030A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013505030A5 JP2013505030A5 JP2012530325A JP2012530325A JP2013505030A5 JP 2013505030 A5 JP2013505030 A5 JP 2013505030A5 JP 2012530325 A JP2012530325 A JP 2012530325A JP 2012530325 A JP2012530325 A JP 2012530325A JP 2013505030 A5 JP2013505030 A5 JP 2013505030A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- fragment
- variant
- derivative
- fusion
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 19
- 229920001184 polypeptide Polymers 0.000 claims description 18
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 18
- 239000012634 fragment Substances 0.000 claims description 14
- 230000004927 fusion Effects 0.000 claims description 14
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 7
- 206010061218 Inflammation Diseases 0.000 claims description 6
- 230000004054 inflammatory process Effects 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 5
- 108090000481 Heparin Cofactor II Proteins 0.000 claims description 2
- 102100030500 Heparin cofactor 2 Human genes 0.000 claims description 2
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 2
- 230000014508 negative regulation of coagulation Effects 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 201000005665 thrombophilia Diseases 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 208000035473 Communicable disease Diseases 0.000 claims 3
- 206010040047 Sepsis Diseases 0.000 claims 3
- 230000005856 abnormality Effects 0.000 claims 3
- 230000002757 inflammatory effect Effects 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 206010040070 Septic Shock Diseases 0.000 claims 2
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims 2
- 208000007536 Thrombosis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000001112 coagulating effect Effects 0.000 claims 2
- 230000015271 coagulation Effects 0.000 claims 2
- 238000005345 coagulation Methods 0.000 claims 2
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 2
- 230000002458 infectious effect Effects 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000002980 postoperative effect Effects 0.000 claims 2
- 230000009885 systemic effect Effects 0.000 claims 2
- 206010003011 Appendicitis Diseases 0.000 claims 1
- 206010051548 Burn infection Diseases 0.000 claims 1
- 206010007882 Cellulitis Diseases 0.000 claims 1
- 206010010741 Conjunctivitis Diseases 0.000 claims 1
- 206010011686 Cutaneous vasculitis Diseases 0.000 claims 1
- 206010012438 Dermatitis atopic Diseases 0.000 claims 1
- 201000000297 Erysipelas Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 102000005720 Glutathione transferase Human genes 0.000 claims 1
- 108010070675 Glutathione transferase Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 201000009906 Meningitis Diseases 0.000 claims 1
- 208000007117 Oral Ulcer Diseases 0.000 claims 1
- 206010033078 Otitis media Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 206010067268 Post procedural infection Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010039085 Rhinitis allergic Diseases 0.000 claims 1
- 206010040943 Skin Ulcer Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 206010044248 Toxic shock syndrome Diseases 0.000 claims 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 208000038016 acute inflammation Diseases 0.000 claims 1
- 230000006022 acute inflammation Effects 0.000 claims 1
- 230000010933 acylation Effects 0.000 claims 1
- 238000005917 acylation reaction Methods 0.000 claims 1
- 230000003044 adaptive effect Effects 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000029936 alkylation Effects 0.000 claims 1
- 238000005804 alkylation reaction Methods 0.000 claims 1
- 201000009961 allergic asthma Diseases 0.000 claims 1
- 230000000172 allergic effect Effects 0.000 claims 1
- 201000010105 allergic rhinitis Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 230000000845 anti-microbial effect Effects 0.000 claims 1
- 208000002399 aphthous stomatitis Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 201000008937 atopic dermatitis Diseases 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000012620 biological material Substances 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- -1 carrier Substances 0.000 claims 1
- 201000001352 cholecystitis Diseases 0.000 claims 1
- 208000037976 chronic inflammation Diseases 0.000 claims 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000007784 diverticulitis Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000032050 esterification Effects 0.000 claims 1
- 238000005886 esterification reaction Methods 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 206010023332 keratitis Diseases 0.000 claims 1
- 206010033072 otitis externa Diseases 0.000 claims 1
- 230000006320 pegylation Effects 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 206010034674 peritonitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000003449 preventive effect Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 208000019206 urinary tract infection Diseases 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0916578.8A GB0916578D0 (en) | 2009-09-22 | 2009-09-22 | Polypeptides and uses thereof |
| GB0916578.8 | 2009-09-22 | ||
| PCT/GB2010/001780 WO2011036444A1 (en) | 2009-09-22 | 2010-09-21 | Heparin cofactor ii fragments with anti-inflammatory and anti-coagulant activity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2013505030A JP2013505030A (ja) | 2013-02-14 |
| JP2013505030A5 true JP2013505030A5 (https=) | 2015-06-18 |
Family
ID=41278086
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012530325A Pending JP2013505030A (ja) | 2009-09-22 | 2010-09-21 | 抗炎症及び抗凝固活性を有するヘパリンコファクターｉｉ断片 |
| JP2012530326A Abandoned JP2013505286A (ja) | 2009-09-22 | 2010-09-22 | ポリペプチド及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012530326A Abandoned JP2013505286A (ja) | 2009-09-22 | 2010-09-22 | ポリペプチド及びその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9169315B2 (https=) |
| EP (2) | EP2480244A1 (https=) |
| JP (2) | JP2013505030A (https=) |
| CN (2) | CN102655874B (https=) |
| AU (2) | AU2010299630A1 (https=) |
| BR (2) | BR112012006502A2 (https=) |
| CA (2) | CA2774288A1 (https=) |
| EA (1) | EA201200515A1 (https=) |
| GB (1) | GB0916578D0 (https=) |
| IN (2) | IN2012DN02981A (https=) |
| MX (1) | MX2012003425A (https=) |
| WO (2) | WO2011036444A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6491880B2 (ja) * | 2011-08-23 | 2019-03-27 | シナプス・ビー．ブイ．Ｓｙｎａｐｓｅ Ｂ．Ｖ． | 異物表面との接触による血液凝固系の活性化の熱安定性阻害剤 |
| RU2476231C1 (ru) * | 2011-10-11 | 2013-02-27 | Федеральное государственное бюджетное учреждение "Российский научный центр "Восстановительная травматология и ортопедия" имени академика Г.А. Илизарова" Министерства здравоохранения и социального развития Российской Федерации | Способ купирования некроза краев кожи послеоперационной раны после эндопротезирования голеностопного сустава |
| GB2500184A (en) * | 2012-03-12 | 2013-09-18 | Ximmune Ab | Polypeptide derived from helix A of heparin cofactor II |
| CN104292309B (zh) * | 2014-09-29 | 2017-04-12 | 广西中医药大学 | 一种小分子多肽 |
| WO2016104436A1 (ja) * | 2014-12-22 | 2016-06-30 | 国立大学法人 岡山大学 | サイトカインストーム抑制剤 |
| RU2606836C2 (ru) * | 2015-03-12 | 2017-01-10 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) | Антикоагулянтный, антитромбоцитарный и фибриндеполимеризационный комплекс на основе гепарина, способ его получения и применение |
| RU2610433C1 (ru) * | 2016-02-17 | 2017-02-10 | Людмила Анисимовна Ляпина | Антикоагулянт |
| CN107875372A (zh) * | 2017-12-20 | 2018-04-06 | 辽宁师范大学 | 重组肽rLj‑112在制备协同肝素抗凝药物中的应用 |
| CN108338163A (zh) * | 2018-03-28 | 2018-07-31 | 陈太师 | 一种持效型杀菌灭藻剂的制备方法 |
| CN112512545A (zh) * | 2018-05-31 | 2021-03-16 | 国立大学法人冈山大学 | 活性氧的产生抑制剂和/或消除促进剂 |
| EP3815706A4 (en) * | 2018-06-28 | 2022-03-16 | National University Corporation Okayama University | AGENT FOR IMPROVING THE CAPACITY OF PHAGOCYTOSIS OF NEUTROPHILS |
| BR112021002725A2 (pt) * | 2018-08-16 | 2021-07-20 | F. Hoffmann-La Roche Ag | métodos para avaliar a fibrilação atrial, para prever o risco de acidente vascular cerebral, para avaliar a eficácia de uma terapia, para identificar um paciente, para monitorar a terapia de anticoagulação e para auxiliar na avaliação da fibrilação atrial, método implementado por computador, kit e uso in vitro |
| CN109432513B (zh) * | 2018-12-12 | 2021-03-23 | 中国医科大学 | 一种具有抗血栓再形成功能的生物材料及其制备方法 |
| US11904000B2 (en) | 2019-05-06 | 2024-02-20 | Brown University | Compositions and methods to enhance cutaneous wound healing |
| CN114364394A (zh) * | 2020-05-26 | 2022-04-15 | 约翰内斯·古滕伯格美因兹大学医学院 | 用于治疗冠状病毒感染及相关凝血病的方法和组合物 |
| CN114113601A (zh) * | 2020-08-25 | 2022-03-01 | 张曼 | 尿液肝素辅因子ii及其多肽片段在烧伤中的应用 |
| CN117683081B (zh) * | 2021-09-24 | 2024-08-06 | 北京昊坤康源医疗科学技术发展有限责任公司 | 一种降血压肽及其在降血压制品上的应用 |
| CN114886116B (zh) * | 2022-03-18 | 2023-11-21 | 广东丸美生物技术股份有限公司 | 一种调理育龄女性健康的组合物及其制备方法和饮料及应用 |
| WO2023212661A1 (en) * | 2022-04-29 | 2023-11-02 | Serpin Pharma, Llc | Serpin peptide derivatives and methods of using the same |
| CN116510074A (zh) * | 2023-03-13 | 2023-08-01 | 西南交通大学 | 一种胆碱磷酸功能化可植入钛支架的制备方法 |
| CN116836233B (zh) * | 2023-08-31 | 2023-11-14 | 中国农业大学 | 抗炎活性多肽及其应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| US5102995A (en) * | 1989-10-20 | 1992-04-07 | Washington University | Dna encoding modified heparin cofactor ii |
| US5118793A (en) * | 1989-10-20 | 1992-06-02 | Washington University | Modified heparin cofactor II |
| US5643872A (en) | 1989-10-23 | 1997-07-01 | Smithkline Beecham Corporation | Cyclic anti-aggregatory peptides |
| AU1873092A (en) * | 1991-04-09 | 1992-11-17 | Brigham And Women's Hospital | Chimeric molecule with plasminogen activator activity and affinity for atherosclerotic plaques |
| US6008058A (en) | 1993-06-18 | 1999-12-28 | University Of Louisville | Cyclic peptide mixtures via side chain or backbone attachment and solid phase synthesis |
| US5589359A (en) | 1994-08-05 | 1996-12-31 | Chiron Corporation | Chimeric proteins |
| US5712247A (en) * | 1995-02-21 | 1998-01-27 | University Of North Carolina | Use of lactoferrin to modulate and/or neutralize heparin activity |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| JPH09176040A (ja) * | 1995-12-27 | 1997-07-08 | Green Cross Corp:The | ヘパリンコファクターｉｉの医薬用途 |
| US6946439B2 (en) * | 1997-02-06 | 2005-09-20 | Entre Med, Inc. | Compositions and methods for inhibiting cellular proliferation comprising TFPI fragments |
| US6207419B1 (en) * | 1998-02-27 | 2001-03-27 | The University Of North Carolina At Chapel Hill | Thrombin inhibitory agents and methods of using same |
| AU1410801A (en) * | 1999-11-17 | 2001-05-30 | Compugen Ltd. | Variants of alternative splicing |
| MXPA04000564A (es) * | 2001-07-20 | 2005-02-17 | Univ Zuerich | Composiciones y metodos para uso de agentes bioactivos derivados de aminoacidos sulfatados y sulfonados. |
| GB0131112D0 (en) | 2001-12-31 | 2002-02-13 | Univ London Pharmacy | Block copolymers |
| WO2003101398A2 (en) * | 2002-05-31 | 2003-12-11 | University Of Utah Research Foundation | Variants of antithrombin iii |
| WO2004047735A2 (en) * | 2002-11-22 | 2004-06-10 | Mang Yu | Broad spectrum anti-viral therapeutics and prophylaxis |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| EP1654545A2 (en) * | 2003-08-08 | 2006-05-10 | Genova Ltd. | Secreted polypeptide species associated with cardiovascular disorders |
| SG150552A1 (en) * | 2004-03-17 | 2009-03-30 | Chiron Corp | Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi) |
| US20050261241A1 (en) * | 2004-05-19 | 2005-11-24 | Celsus Biopharmaceuticals, Inc. | Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses |
| WO2006122139A2 (en) * | 2005-05-06 | 2006-11-16 | Novartis Ag | Use of tfpi to treat severe bacterial infections |
| WO2007014199A2 (en) * | 2005-07-22 | 2007-02-01 | Novartis Ag | Tfpi fragments as anti-microbial agents |
| SI1981519T1 (en) * | 2005-12-29 | 2018-05-31 | Dyax Corp. | INHIBITION PROTEAZE |
| ES2431526T3 (es) * | 2005-12-29 | 2013-11-26 | The Regents Of The University Of California Office Of Technology Transfer | Procedimientos y composiciones relacionadas con el dominio Kunitz I mutante de TFPI-2 |
| JP2009526046A (ja) * | 2006-02-10 | 2009-07-16 | デルマゲン アクティエボラーグ | 新規分子 |
| BRPI0810172A2 (pt) * | 2007-04-13 | 2014-10-14 | Catalyst Biosciences Inc | Polipeptídeos de fator vii modificado e seus usos |
| JP2010534563A (ja) * | 2007-07-24 | 2010-11-11 | ネクスバイオ，インク． | マイクロ粒子の作製のための技術 |
-
2009
- 2009-09-22 GB GBGB0916578.8A patent/GB0916578D0/en not_active Ceased
-
2010
- 2010-09-21 EA EA201200515A patent/EA201200515A1/ru unknown
- 2010-09-21 AU AU2010299630A patent/AU2010299630A1/en not_active Abandoned
- 2010-09-21 MX MX2012003425A patent/MX2012003425A/es not_active Application Discontinuation
- 2010-09-21 WO PCT/GB2010/001780 patent/WO2011036444A1/en not_active Ceased
- 2010-09-21 CN CN201080052695.8A patent/CN102655874B/zh not_active Expired - Fee Related
- 2010-09-21 CA CA2774288A patent/CA2774288A1/en not_active Abandoned
- 2010-09-21 US US13/497,006 patent/US9169315B2/en not_active Expired - Fee Related
- 2010-09-21 IN IN2981DEN2012 patent/IN2012DN02981A/en unknown
- 2010-09-21 JP JP2012530325A patent/JP2013505030A/ja active Pending
- 2010-09-21 EP EP10777056A patent/EP2480244A1/en not_active Withdrawn
- 2010-09-21 BR BR112012006502A patent/BR112012006502A2/pt not_active IP Right Cessation
- 2010-09-22 BR BR112012006501A patent/BR112012006501A8/pt not_active IP Right Cessation
- 2010-09-22 CA CA2774296A patent/CA2774296A1/en not_active Abandoned
- 2010-09-22 JP JP2012530326A patent/JP2013505286A/ja not_active Abandoned
- 2010-09-22 WO PCT/GB2010/001781 patent/WO2011036445A2/en not_active Ceased
- 2010-09-22 EP EP10777057A patent/EP2480564A2/en not_active Withdrawn
- 2010-09-22 CN CN2010800527096A patent/CN102639556A/zh active Pending
- 2010-09-22 IN IN3368DEN2012 patent/IN2012DN03368A/en unknown
- 2010-09-22 US US13/497,195 patent/US20120189673A1/en not_active Abandoned
- 2010-09-22 AU AU2010299631A patent/AU2010299631A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013505030A5 (https=) | ||
| JP2013505286A5 (https=) | ||
| WO2011036444A4 (en) | Heparin cofactor ii fragments with anti-inflammatory and anti-coagulant activity | |
| Gallo et al. | Biology and clinical relevance of naturally occurring antimicrobial peptides | |
| Bals et al. | The innate immune system in cystic fibrosis lung disease | |
| JP5330230B2 (ja) | 改良型抗菌ペプチド | |
| Leth-Larsen et al. | Surfactant protein D (SP-D) serum levels in patients with community-acquired pneumonia | |
| Kishore et al. | Surfactant proteins SP-A and SP-D in human health and disease | |
| JP6007106B2 (ja) | 炎症性腸疾患（ｉｂｄ）及び過敏性腸症候群（ｉｂｓ）の予防及び治療のための組換体プロバイオティック細菌 | |
| JP2009526045A (ja) | 新規抗菌ペプチド及びその使用 | |
| JP2009526046A (ja) | 新規分子 | |
| US20130052258A1 (en) | Polypeptides and uses thereof | |
| CN105722524B (zh) | 用于重组人分泌球蛋白的改进方法 | |
| KR20070108142A (ko) | 신규한 항미생물성 펩타이드 | |
| Ishikawa et al. | Precursor processing of human defensin-5 is essential to the multiple functions in vitro and in vivo | |
| CN101448851B (zh) | 改进的抗微生物肽 | |
| JP2008505852A5 (https=) | ||
| Gupta et al. | Collectins and ficolins | |
| CN108165567A (zh) | 人溶菌酶基因的合成及其表达产物的构建方法 | |
| Manolov et al. | Moraxella-dependent α1-antichymotrypsin neutralization: A unique virulence mechanism | |
| Saxena | Lung surfactant: The indispensable component of respiratory mechanics | |
| JPWO2007049770A1 (ja) | 緑膿菌の外膜タンパク質ｐａ５１５８ | |
| Bresner | The Quantity and Structural Quality of SP-A and SP-D Present in the Airways of Influenza-Infected Patients | |
| Miyamoto et al. | Development of enzyme-linked immunosorbent assay for bovine surfactant protein D in bronchoalveolar lavage fluid | |
| Glucosamine | Mannose-Binding Lectin Recognizes |